These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 21784113

  • 1. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination.
    Verheul RJ, Slütter B, Bal SM, Bouwstra JA, Jiskoot W, Hennink WE.
    J Control Release; 2011 Nov 30; 156(1):46-52. PubMed ID: 21784113
    [Abstract] [Full Text] [Related]

  • 2. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
    Slütter B, Bal S, Keijzer C, Mallants R, Hagenaars N, Que I, Kaijzel E, van Eden W, Augustijns P, Löwik C, Bouwstra J, Broere F, Jiskoot W.
    Vaccine; 2010 Aug 31; 28(38):6282-91. PubMed ID: 20638455
    [Abstract] [Full Text] [Related]

  • 3. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations.
    Bal SM, Slütter B, van Riet E, Kruithof AC, Ding Z, Kersten GF, Jiskoot W, Bouwstra JA.
    J Control Release; 2010 Mar 19; 142(3):374-83. PubMed ID: 19932723
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice.
    Bal SM, Slütter B, Verheul R, Bouwstra JA, Jiskoot W.
    Eur J Pharm Sci; 2012 Mar 12; 45(4):475-81. PubMed ID: 22009113
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen.
    Slütter B, Soema PC, Ding Z, Verheul R, Hennink W, Jiskoot W.
    J Control Release; 2010 Apr 19; 143(2):207-14. PubMed ID: 20074597
    [Abstract] [Full Text] [Related]

  • 9. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
    Sayin B, Somavarapu S, Li XW, Thanou M, Sesardic D, Alpar HO, Senel S.
    Int J Pharm; 2008 Nov 03; 363(1-2):139-48. PubMed ID: 18662762
    [Abstract] [Full Text] [Related]

  • 10. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination.
    Slütter B, Jiskoot W.
    J Control Release; 2010 Nov 20; 148(1):117-121. PubMed ID: 20600405
    [Abstract] [Full Text] [Related]

  • 11. Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: Impact of formulation on physicochemical and immunological characteristics.
    Tafaghodi M, Saluja V, Kersten GF, Kraan H, Slütter B, Amorij JP, Jiskoot W.
    Vaccine; 2012 Aug 03; 30(36):5341-8. PubMed ID: 22749834
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tailorable thiolated trimethyl chitosans for covalently stabilized nanoparticles.
    Verheul RJ, van der Wal S, Hennink WE.
    Biomacromolecules; 2010 Aug 09; 11(8):1965-71. PubMed ID: 20578733
    [Abstract] [Full Text] [Related]

  • 15. Small is beautiful: N-trimethyl chitosan-ovalbumin conjugates for microneedle-based transcutaneous immunisation.
    Bal SM, Slütter B, Jiskoot W, Bouwstra JA.
    Vaccine; 2011 May 23; 29(23):4025-32. PubMed ID: 21443959
    [Abstract] [Full Text] [Related]

  • 16. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system.
    Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W.
    J Control Release; 2006 Mar 10; 111(1-2):107-16. PubMed ID: 16380189
    [Abstract] [Full Text] [Related]

  • 17. TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines.
    Sayin B, Somavarapu S, Li XW, Sesardic D, Senel S, Alpar OH.
    Eur J Pharm Sci; 2009 Nov 05; 38(4):362-9. PubMed ID: 19733658
    [Abstract] [Full Text] [Related]

  • 18. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK, Tomar P, Sharma V, Dixit VK.
    Vaccine; 2011 Nov 08; 29(48):9026-37. PubMed ID: 21939718
    [Abstract] [Full Text] [Related]

  • 19. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
    Hagenaars N, Verheul RJ, Mooren I, de Jong PH, Mastrobattista E, Glansbeek HL, Heldens JG, van den Bosch H, Hennink WE, Jiskoot W.
    J Control Release; 2009 Dec 03; 140(2):126-33. PubMed ID: 19712713
    [Abstract] [Full Text] [Related]

  • 20. Antigen-conjugated N-trimethylaminoethylmethacrylate chitosan nanoparticles induce strong immune responses after nasal administration.
    Liu Q, Zheng X, Zhang C, Shao X, Zhang X, Zhang Q, Jiang X.
    Pharm Res; 2015 Jan 03; 32(1):22-36. PubMed ID: 24970313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.